Medtronic plc stock (IE00BTN1Y115): CEO equity award conversion and current valuation metrics in focus

Medtronic plc, listed on the New York Stock Exchange under the ticker MDT, traded near USD 75.76 on 05/29/2026 in New York, with the price up about 0.6% intraday from the session low and roughly 1.0% below the high, according to Robinhood as of 05/29/2026.Robinhood as of 05/29/2026

The move comes as investors in the United States review fresh insider information after a recent Form 4 filing showed that Medtronic’s chairman and chief executive Geoffrey Martha converted performance share units into ordinary shares on 05/26/2026, a transaction tied to long-term incentive compensation rather than open-market buying or selling, according to SEC data summarized by StockTitan as of 05/29/2026.StockTitan as of 05/29/2026

The stock traded at about USD 75.76 on 05/29/2026 on the NYSE, giving the Ireland-headquartered medical technology group a market capitalization of roughly USD 97.0 billion, with a reported price-to-earnings ratio near 21.2 and a dividend yield around 3.7%, based on Robinhood data as of 05/29/2026.Robinhood as of 05/29/2026

In the German market, Medtronic is also accessible for investors via secondary listings such as Tradegate, where the shares are typically quoted in euro, offering an additional route for European investors who prefer local trading venues and EUR settlement.

The recent insider filing states that Martha settled 85,461 performance-vesting share units into ordinary shares on 05/26/2026, following certification of performance on 04/24/2026, and that his direct holdings after the transaction stood at 343,099 ordinary shares, including 1,743 shares acquired by dividend reinvestment since the prior report, according to the SEC Form 4 as summarized by StockTitan on 05/29/2026.StockTitan as of 05/29/2026

The filing clarifies that each performance share unit represented a contingent right to receive one ordinary share of Medtronic, granted originally on 07/31/2023, and that the settlement reflects compensation earned under the company’s long-term incentive plan rather than a public market purchase or disposal, which is relevant for how investors interpret insider activity as of late May 2026.StockTitan as of 05/29/2026

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

Medtronic plc: core business model

Medtronic focuses on developing and commercializing a broad portfolio of implantable devices and minimally invasive therapies that target chronic cardiovascular, neurological, surgical, and metabolic conditions, with sales largely driven by procedure volumes and adoption of its branded platforms in hospitals and clinics worldwide.

Valuation metrics and multiples for Medtronic plc

On a headline basis, Medtronic’s share price of about USD 75.76 on 05/29/2026 implies a trailing price-to-earnings multiple close to 21.2, based on Robinhood’s market snapshot, positioning the stock within a typical range for large-cap US-listed medical technology peers that combine steady cash flows with ongoing R&D investment.Robinhood as of 05/29/2026

The same data point indicates an annualized dividend yield of roughly 3.7% as of 05/29/2026, which is relatively high compared with many growth-oriented healthcare equipment names and reflects Medtronic’s role as an income-generating blue chip in the US and European medical technology landscape.Robinhood as of 05/29/2026

Conclusion

Medtronic’s share price in the mid-70 USD range on 05/29/2026, combined with a price-to-earnings multiple slightly above 21 and a dividend yield near 3.7%, highlights how the market is currently positioning the stock between income-focused blue chips and growth-oriented medical technology names.

The recent Form 4 detailing CEO Geoffrey Martha’s conversion of performance share units into ordinary shares offers investors an updated view of executive equity exposure while not signaling an open-market transaction, which may influence how the insider activity is interpreted alongside the valuation metrics.

Against this backdrop, investors observing Medtronic will likely weigh the company’s earnings trajectory, capital allocation policy, and broader healthcare device demand trends when considering the valuation indicators that frame the stock as of late May 2026.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.